Premium
Protective immunity induced by an intranasal multivalent vaccine comprising 10 Lactococcus lactis strains expressing highly prevalent M‐protein antigens derived from Group A Streptococcus
Author(s) -
Wozniak Aniela,
Scioscia Natalia,
García Patricia C.,
Dale James B.,
Paillavil Braulio A.,
Legarraga Paulette,
SalazarEchegarai Francisco J.,
Bueno Susan M.,
Kalergis Alexis M.
Publication year - 2018
Publication title -
microbiology and immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.664
H-Index - 70
eISSN - 1348-0421
pISSN - 0385-5600
DOI - 10.1111/1348-0421.12595
Subject(s) - streptococcus pyogenes , lactococcus lactis , biology , microbiology and biotechnology , nasal administration , virology , immunization , streptococcaceae , immunity , group a , antibody , antigen , streptococcus , virulence , pharyngitis , immunology , immune system , bacteria , medicine , staphylococcus aureus , lactic acid , genetics , antibiotics , biochemistry , pathology , gene
Streptococcus pyogenes (group A Streptococcus ) causes diseases ranging from mild pharyngitis to severe invasive infections. The N‐terminal fragment of streptococcal M protein elicits protective antibodies and is an attractive vaccine target. However, this N‐ terminal fragment is hypervariable: there are more than 200 different M types. In this study, an intranasal live bacterial vaccine comprising 10 strains of Lactococcus lactis , each expressing one N‐terminal fragment of M protein, has been developed. Live bacterial‐vectored vaccines cost less to manufacture because the processes involved are less complex than those required for production of protein subunit vaccines. Moreover, intranasal administration does not require syringes or specialized personnel. Evaluation of individual vaccine types (M1, M2, M3, M4, M6, M9, M12, M22, M28 and M77) showed that most of them protected mice against challenge with virulent S. pyogenes . All 10 strains combined in a 10‐valent vaccine (M×10) induced serum and bronchoalveolar lavage IgG titers that ranged from three‐ to 10‐fold those of unimmunized mice. After intranasal challenge with M28 streptococci, survival of M×10‐immunized mice was significantly higher than that of unimmunized mice. In contrast, when mice were challenged with M75 streptococci, survival of M×10‐immunized mice did not differ significantly from that of unimmunized mice. Mx‐10 immunized mice had significantly less S. pyogenes in oropharyngeal washes and developed less severe disease symptoms after challenge than did unimmunized mice. Our L. lactis ‐based vaccine may provide an alternative solution to development of broadly protective group A streptococcal vaccines.